Investigational · not FDA approved

Editorially reviewed · Last updated June 2026 · How we review

Stopping Retatrutide: What Happens When You Come Off

There is no published trial that follows people after they stop retatrutide — its Phase 2 study (NEJM 2023) ended treatment at 48 weeks with only a 4-week safety follow-up, and the Phase 3 TRIUMPH program is still running. So the honest answer to "what happens when I stop?" comes from two places: the withdrawal data for the closely related drug tirzepatide (the SURMOUNT-4 randomized withdrawal trial), and what retatrutide's own trial tells us about how the body behaves on the drug.

Both point to the same conclusion: GLP-class weight loss is maintained by the drug, not cured by it. When the medication stops, appetite returns and a substantial share of the lost weight comes back unless something else holds it in place. This page lays out the regain numbers, the symptoms people report on coming off, and the two realistic exit routes — stopping entirely versus transitioning to a maintenance agent.

How Much Weight Comes Back: The SURMOUNT-4 Evidence

Retatrutide has no published withdrawal trial. The best available evidence is SURMOUNT-4 (JAMA 2024), a Phase 3 randomized withdrawal study of tirzepatide — the dual agonist that shares two of retatrutide's three receptor targets (GLP-1 and GIP). Participants lost a mean 20.9% of body weight over a 36-week lead-in, then were randomized either to keep taking tirzepatide or to switch to placebo for 52 more weeks.

From week 36 (randomization)	Continued drug	Switched to placebo
Weight change, weeks 36–88	−5.5% (kept losing)	+14.0% (regained)
Difference between groups	−19.4 percentage points (95% CI −21.2 to −17.7)
Maintained at least 80% of lost weight	89.5%	16.6%
Overall weight reduction, week 0–88	25.3%	9.9%

The takeaway: people who stopped regained on average 14% of their body weight within a year, and only about 1 in 6 held onto most of their loss. People who stayed on the drug kept losing. Withdrawing the medication did not freeze the result in place — it reversed a large part of it.

Retatrutide is expected to behave at least as dramatically on withdrawal, for a specific reason described below.

Why Retatrutide May Regain Faster Than Other GLP-Drugs

In the NEJM Phase 2 trial, retatrutide produced the largest weight loss reported for any anti-obesity drug in a study of a year or less — a mean 24.2% at the 12-mg dose by week 48. Critically, the trial investigators noted that the weight-loss curve had not yet reached a plateau when treatment was stopped at 48 weeks: participants were still actively losing weight when the drug was withdrawn.

That matters for stopping. A steeper, still-climbing weight-loss trajectory implies a larger appetite-suppression effect being held down by the drug — and therefore a larger rebound when that suppression is removed. Retatrutide's regain risk should be viewed as at least as high as tirzepatide's SURMOUNT-4 numbers, not lower, even though no head-to-head withdrawal data exists yet.

Symptoms People Report When Coming Off

Two categories of effect reverse when the drug clears (retatrutide's half-life is about 6 days, so it is largely gone within roughly a month):

Appetite and "food noise" return. The hunger and craving suppression is a direct pharmacological effect. As drug levels fall, appetite returns — often described as food noise "switching back on." This is the mechanism behind the regain numbers above, not a failure of willpower.
On-drug side effects fade. The dose-dependent heart-rate increase seen on retatrutide peaked at 24 weeks and then declined even while participants stayed on the drug; on stopping, the cardiovascular and GI effects of the medication resolve as it clears.

Community reports of mood changes (low mood, apathy, anhedonia) easing after cycling off, or of elevated resting heart rate and sleep disruption persisting at low doses, are anecdotal — they are not measured endpoints in any retatrutide trial and should be treated as individual experiences, not established effects.

Two Ways to Come Off

Option 1 — Stop entirely

Discontinuing without a replacement is the scenario SURMOUNT-4 measured directly: expect appetite to return and meaningful regain over the following year unless diet, training, and other supports are strong enough to substitute for the drug's appetite control. There is no evidence that any taper schedule prevents regain — regain is driven by the loss of appetite suppression, not by a withdrawal syndrome.

Option 2 — Transition to a maintenance agent

Some people move from retatrutide to a lower-intensity or maintenance drug (for example, a lower-dose GLP-1 or dual agonist) rather than stopping outright, on the logic that continued treatment maintains the loss — exactly what SURMOUNT-4's continued-drug arm showed. This is a clinical decision: there is no published protocol for switching off retatrutide onto a maintenance agent, and dose equivalence between these drugs is not established. (Our switching to retatrutide page covers the inbound direction — moving onto retatrutide from another GLP-1.)

Either route should be planned with a prescriber. The point of this page is the realistic expectation, not a recommendation.

Frequently Asked Questions

Will I gain the weight back if I stop retatrutide?

Most likely a substantial portion, yes. There is no retatrutide-specific withdrawal trial, but in SURMOUNT-4 — the Phase 3 withdrawal study of the closely related drug tirzepatide — people who switched to placebo regained a mean 14% of body weight within a year, and only 16.6% kept at least 80% of their loss (versus 89.5% of those who stayed on the drug). Retatrutide produces even larger weight loss with a curve that had not plateaued at 48 weeks, so its regain risk should be considered at least as high.

Should you cycle retatrutide — stop once you hit your goal weight, then maintain on lifestyle?

Cycling on and off is a common plan, but the evidence says each off-period brings the weight back rather than locking the loss in. No trial has tested cycling retatrutide; the closest data is SURMOUNT-4, which compared continuing tirzepatide against stopping it. People who stopped regained a mean 14.0% of body weight within a year and only 16.6% kept at least 80% of their loss, while those who continued kept 89.5%. The drug maintains the result; it does not cure the appetite drive underneath it. Retatrutide's weight-loss curve had not even plateaued at 48 weeks in its Phase 2 trial, so the rebound after each off-cycle should be expected to be at least as steep. If your goal is to come off, the realistic options are stopping entirely (and substituting diet and training) or transitioning to a maintenance agent — both planned with a prescriber — not a stop-start cycle that resets the regain each time.

How long does retatrutide stay in your system after the last dose?

Retatrutide has a half-life of approximately 6 days, so the drug is largely cleared from the body within about a month of the final injection. Appetite suppression fades as drug levels fall over that period rather than disappearing overnight.

Do I need to taper off retatrutide?

There is no evidence that any taper schedule prevents weight regain, because regain is caused by the return of appetite as the drug clears — not by a withdrawal syndrome. Some prescribers reduce the dose gradually for tolerability or to ease the transition, but tapering is a clinical decision; talk to your doctor.

Should I switch to a maintenance medication instead of stopping?

Continued treatment is what maintains the loss — in SURMOUNT-4, people who kept taking the drug kept the weight off, while those who stopped regained. Some people transition from retatrutide to a lower-intensity maintenance agent for this reason, but there is no published switching protocol and no established dose equivalence between these drugs, so this should be planned with a prescriber.

Is there any retatrutide-specific data on stopping?

Not yet. Retatrutide's Phase 2 trial ended treatment at 48 weeks with only a 4-week safety follow-up — it did not track participants long enough after stopping to report regain. The Phase 3 TRIUMPH program is still ongoing. Until that data is published, the SURMOUNT-4 tirzepatide withdrawal results are the closest evidence available.

For on-treatment adverse events (as opposed to stop/regain symptoms), see Retatrutide side effects & safety.

Sources

Aronne, L.J., et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38–48. Full text.
Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 389, 514–526. DOI: 10.1056/NEJMoa2301972.

Questions to ask your doctor

Given my health history, is a GLP-1 medication appropriate for me at all?
Which approved option (e.g. semaglutide, tirzepatide) best fits my goals?
What starting dose and titration pace would you use, and why?
What side effects should I watch for, and when should I call you?
How will we monitor whether it's working and when to adjust?

How we keep this honest

What this is: Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status: Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard: Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties: We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources

Grounded in primary sources

NEJM

The Lancet

JAMA

FDA

ClinicalTrials.gov

Switching to Retatrutide from Tirzepatide or Semaglutide

Retatrutide is not yet available, but here is what we know about switching between GLP-1 drugs and how to access clinical trials.

Guide

Retatrutide Dosage & Dosing Guide: Titration, Missed Doses, Taper

Phase 3 titration schedule (2→4→6→9→12 mg), missed-dose protocol, taper guidance, and dose-by-dose weight loss data.

Safety

Retatrutide Side Effects & Safety Data (2026)

Trial incidence for retatrutide (reta) side effects — GI rates, dysesthesia, and class-level safety concerns.

Explainer

Retatrutide Results: Weight Loss Data and What to Expect

28.3% average weight loss at 80 weeks in the pivotal Phase 3 trial — here's the full data breakdown by dose, timeline, and what individual results look like.

Keep exploring

Explore all guides topics →